Volumetric tumor growth in advanced non‐small cell lung cancer patients with EGFR mutations during EGFR‐tyrosine kinase inhibitor therapy

摘要: BACKGROUND The objective of this study was to define the volumetric tumor growth rate in patients who had advanced nonsmall cell lung cancer (NSCLC) with sensitizing epidermal factor receptor (EGFR) mutations and initially received treatment EGFR-tyrosine kinase inhibitor (TKI) therapy beyond progression. METHODS The included 58 NSCLC EGFR treated first-line gefitinib or erlotinib, baseline computed tomography (CT) scans available that revealed a measurable lesion, at least 2 follow-up CT during TKI therapy, experienced growth. The volume (in mm3) dominant lesion measured on therapy. In total, 405 measurements were analyzed linear mixed-effects model, fitting time as random effect, logarithm (logeV). RESULTS A model fitted predict logeV, adjusting for months from baseline. LogeV estimated function among whose tumors started growing after nadir: logeV = 0.12*time + 7.68. formula, regression coefficient time, 0.12/month, represents logeV (standard error, 0.015/month; P < .001). When adjusted volume, logeV0, also 0.12/month P < .001; logeV = 0.12*months + 0.72 logeV0 + 0.61). CONCLUSIONS Tumor models defined nadir EGFR-mutant, receiving TKI, providing reference value progress results can be studied further additional cohorts develop practical criteria help identify are slowly progressing safely remain EGFR-TKIs. Cancer 2013;119:3761–3768. © 2013 American Society.